In the IMvigor011 trial, ctDNA-guided adjuvant atezolizumab reduced the risk of disease recurrence or death by 36% and the ...
Personalized health is the holy grail, but there’s a long way to go before algorithms can factor in chronic conditions. is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results